A Study to Investigate LYL845 in Adults With Solid Tumors

Summary

This is an open-label, multi-center, dose-escalation study with expansion cohorts, designed to evaluate the safety and anti-tumor activity of LYL845, an epigenetically reprogrammed tumor infiltrating lymphocyte (TIL) therapy, in participants with relapsed or refractory (R/R) metastatic or locally advanced melanoma, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC).

Timeline

Start

2022-12-19

Primary completion

2025-01-09

Completion

2025-01-09

Outcome

Outcome not reported

Stopped: “Pipeline Reprioritization”

Drugs

Indications